Despite an incidence of 1% among women under the age of 40, primary ovarian insufficiency (POI) is still poorly understood. As the variable cause and presentation of POI complicate its management, a standard regimen for treatment remains to be established. However, emerging research has provided new insight on current mainstays of treatment as well as novel management approaches and therapeutic interventions.
INTRODUCTION
Primary ovarian insufficiency (POI), interchangeably termed 'premature menopause' or 'premature ovarian failure', is defined as the acquisition of hypergonadotropic hypogonadism in women before the age of 40 [1] . The incidence of spontaneous POI is estimated at one in 250 for women under 35 years of age and one in 100 for women under 40 years of age [2] . The classical presentation of POI includes symptoms associated with estrogen deficiency (i.e., vaginal dryness and hot flashes), menstrual irregularity (oligomenorrhea or amenorrhea), elevated serum gonadotropins, low serum estradiol, and impaired fertility. As women with POI are at an increased risk for a number of chronic sequelae including cardiovascular disease and osteoporosis, early diagnosis and management are critical to prevent the adverse effects of estrogen deficiency. However, as the variable cause and presentation of POI may complicate its management, a standard regimen for treatment remains to be established. The purpose of this review is to discuss updates on the management of POI.
MANAGEMENT
As previously described, POI is associated with a number of potential long-term sequelae including infertility, neurocognitive disorders, and an increased mortality risk. Additionally, women diagnosed with POI, in comparison to controls, have a higher reported incidence of psychological stress, anxiety, depression, as well as reduced sexual and general well-being [3 & ]. Given the complexity of this condition, a wide variety of treatment regimens have been recommended; however, none have provided enough evidence to be established as the best practice. A multidimensional approach to POI management that includes medical treatment, psychosocial support, and preventive care may address the
Hormonal replacement therapy
In the absence of contraindications, hormonal replacement therapy (HRT) is strongly advised for not only the treatment of menopausal-related symptoms, but also to reduce the risk of long-term sequelae and neurocognitive function [4 & ]. Previous literature has compared the efficacy of standard sex steroid replacement (sSSR) with physiological sex steroid replacement (pSSR) in managing POI [5-9]. By definition, sSSR comprises treatment regimens made up of synthetic hormonal derivatives, primarily oral ethinylestradiol or combined oral contraceptive pills, and were initially utilized for managing symptoms in postmenopausal women. pSSR is characterized as a regimen that includes transdermal estradiol and vaginal progesterone supplementation, and its administration is designed to replicate the natural changes in hormonal levels observed in women with normal ovarian function.
Recent findings indicate that pSSR may be more effective than sSSR in managing POI. sSSR regimens have been shown to treat especially menopausal symptoms, but are not limited to vasomotor symptoms and vaginal atrophy; however, they may be inadequate in maintaining skeletal and cardiovascular health as well as improving fertility [10 & ]. In a recent trial comparing improvements in uterine and endometrial parameters between sSSR and pSSR regimens among women with POI, usage of pSSR resulted in a greater mean endometrial thickness compared with sSSR after 3 months of treatment (4.8 mm vs. 3.0 mm, respectively; P ¼ 0.002), thereby indicating a greater improvement in endometrial functional response [11] . The study also reported a relatively greater increase in uterine volume for the pSSR regimen compared with sSSR; however, this increase was not statistically significant (P ¼ 0.070). However, this lack of significance may be explained by the etiological make-up of the study group as the levels of improvement in uterine parameters associated with pSSR may depend on POI cause [8] . Therefore, as uterine, endometrial, and hypothalamic-pituitary-gonadal functioning must be optimized to increase the probability of successful fertility treatment [9], POI patients desiring fertility preservation or pregnancy may benefit from a pSSR regimen. Further research is needed, however, to determine optimal administration protocols for improved success with donor egg therapy. Another recent clinical trial that compared the effect of combined estrogen/progestin therapy in POI patients on BMD with controls with normal ovarian function reported that transdermal estradiol and MPA (used in pSSR and sSSR, respectively) after 3 years of treatment maintained BMD in the femoral neck and lumbar spine as well as controls, and restored BMD in the same areas to levels seen in women with normal ovarian function [12 & ]. As the administered hormonal dosing schedule of transdermal estradiol and MPA in this trial is the same regimen most widely used in clinical practice, these findings should help to advocate for prompt treatment and patient compliance.
Preserving neurocognitive function
Neurocognitive decline has been reported in the setting of estrogen deficiency [13] [14] [15] [16] . A recent population-based cohort study of menopausal women reported that menopause at or before the age of 40 because of premature bilateral ovariectomy or POI was associated with decreased verbal fluency
KEY POINTS
Women with POI seeking fertility may benefit from pSSR; however, further research is needed to determine optimal administration protocols for improved success with donor egg therapy.
As transdermal estradiol and medroxyprogesterone acetate (MPA) have been shown to restore and maintain bone mineral density (BMD) in women with POI, educating patients prescribed the regimen on the benefits of long-term treatment compliance is recommended.
Because of the lack of regulation and the most recently reported research regarding CBHs, providers should prioritize patient counseling to inform women diagnosed with POI who are considering the therapy about its risks.
Further efforts to establish standardized assessment methods and reference values are needed to effectively utilize bone turnover markers for monitoring BMD over the course of managing patients diagnosed with POI.
Although bupropion does not directly treat estrogen deficiency, it shows promise for POI patients diagnosed with depression in preventing osteoporotic sequelae.
Though autologous ovarian tissue harvesting, cryopreservation, and subsequent in-vitro maturation and fertilization techniques are experimental, cryopreserved donor oocyte should be considered.
(odds ratio 1.56, 95% CI 1.12-1.87, P ¼ 0.004) and visual memory (odds ratio 1.39, 95% CI 1.09-1.77, P ¼ 0.007) in later life compared with natural menopause after age 40 [17 & ]. After 7 years of follow-up, both surgical and nonsurgical menopause occurring before the age of 40 was associated with a 35% increased risk for significant reductions in psychomotor speed and global cognitive function; however, no significant associations between surgical status groups and these risks were observed. Additionally, HRT did not counteract the negative cognitive effects when taken during premature menopause; however, it may potentially benefit visual memory. As such, timely diagnosis and treatment of POI should continue to be greatly stressed as a means to prevent the detrimental neurocognitive effects of estrogen deficiency that are observed later in life.
Androgens in primary ovarian insufficiency
Androgen supplementation, particularly testosterone, and its usage in improving general and sexual well-being has been investigated [18] , but research recommending its usage is controversial. Because of lack of evidence on its safety for long-term usage as well as efficacy, it is not recommended for women with POI. Additionally, no Food and Drug Administration (FDA)-approved products specifically designed for women with POI have been developed. In a recent study investigating the effects of physiologic testosterone supplementation (150 mg patch) added to an estrogen/progestin regimen among women with POI, no improvements in quality of life, self-esteem, or mood symptoms were observed after 12 months of treatment relative to controls only receiving estrogen/progestin replacement [19 & ]. Based on these findings, there does not appear to be an androgen-related deficiency in the setting of POI. Additionally, although testosterone has been shown to improve BMD in androgen-deficient men, 150 mg transdermal testosterone added to estrogen/progestin has not shown any additional benefit in maintaining or restoring BMD in women with POI compared with estrogen/progestin alone
Compounded bioidentical hormones
In the wake of findings reported by the Women's Health Initiative stating an increased risk of breast cancer and stroke among menopausal women taking HRT, the usage of compounded bioidentical hormone (CBH) greatly increased because of its claims of being a more natural alternative treatment with fewer risks [20] and more effective because of its customized preparation of bioidentical hormones for individual patients. [22] . Mean steady state estradiol levels differed significantly between the conventional regimen and the 2.5 mg Biest arm, which is the most common dosage of Biest prescribed (P < 0.05). Additionally, none of the three Biest doses reached the minimum serum estradiol level of 40 pg/ml recommended for protection against postmenopausal bone loss [23 & ]. Such findings highlight potential inadequacies of CBH in not only alleviating menopausal symptoms, but also maintaining bone and cardiovascular health and preventing chronic sequelae in women with POI. According to a recent survey, approximately 1-2.5 million women aged 40 years or older are estimated to be using CBH therapy in the USA with 86% reporting that they are not aware that their therapy was not evaluated or approved by the FDA, and 27% reporting uncertainty as to whether their therapy was customized to their hormone levels [24] . Because of the lack of regulation and the most recently reported research, providers should prioritize patient counseling to inform women diagnosed with POI who are considering CBH therapy about its risks.
Dehydroepiandrosterone
Dehydroepiandrosterone (DHEA) has been proposed as an alternative hormonal therapeutic for improvement in ovarian function. In a recent clinical trial investigating the effects of DHEA on women with POI through an assessment of ovarian response markers, DHEA significantly increased antral follicle count after 16 weeks of treatment, but did not significantly affect anti-mullerian hormone or follicle stimulating hormone levels [25] . Nonetheless, DHEA supplementation shows promise in managing POI and warrants further clinical investigation through randomized controlled trials with longer follow-up durations for a more comprehensive assessment of its efficacy.
FERTILITY TREATMENT OPTIONS

Donor oocytes
Though techniques in fertility preservation for women with POI are still being developed, cryopreserved donor oocyte with in-vitro fertilization (IVF) should be considered. Historically, fresh donor egg IVF cycles have resulted in high (88%) cumulative pregnancy rate after four cycles [26] . With the development of vitrification, a fast-freeze technique, use of cryopreserved donor oocytes is an option in addition to fresh ovum donation. Rates of post-thaw fertilization, pregnancy, and live birth rates are comparable to fresh donor cycles [27] , though no studies have been published on the outcomes in women with premature ovarian insufficiency.
Fertility preservation
Although it remains an investigational method of fertility preservation, ovarian tissue cryopreservation using vitrification with subsequent autotransplantation may be useful in young, particularly prepubertal POI patients, which allows for immature oocyte preservation in early ovarian follicles. Thus, a population of mature oocytes could be generated from the early follicles should they successfully develop into preovulatory follicles following transplantation. In a recent publication, nine out of 24 women with POI exhibiting residual follicles presented with successful follicle growth after graft transplantation beneath fallopian tubes [28] . Subsequent IVF and embryo transfer in four of these patients resulted in three pregnancies, of which two resulted in successful deliveries. While the authors report further research on determining the most optimal autografting locations along with detecting residual follicle count in POI patients, cryopreservation of one ovary through this method may serve as a means of early fertility preservation in young patients, thereby allowing them to explore noninvasive fertility procedures before undergoing autotransplantation.
Autoimmune endocrinopathy screening
Of the autoimmune disorders, POI is most commonly associated with thyroiditis and autoimmune polyendocrine syndrome, which can include hypothyroidism, adrenal insufficiency, hypoparathyroidism, and type I diabetes mellitus [29] . To screen for asymptomatic autoimmune adrenal insufficiency, serum antiadrenal and anti-21 hydroxylase antibodies should be measured in all women once they are diagnosed with POI and have a confirmed normal karyotype. Furthermore, anti-21 hydroxylase antibodies may also serve to diagnose autoimmune oophoritis. However, in rare cases, 21-hydroxlase antibodies may conflict with a positive antiadrenal antibody test by showing a negative result because of the presence of antibodies to other steroidogenic enzymes such as 17-hyroxylase [30] . Although screening for adrenal antibodies is available [29] , a reliable, standardized screening test for ovarian antibodies has yet to be established, and thus the prevalence of autoimmune oophoritis in the absence of adrenal autoimmunity among women with POI is currently unknown. Additionally, normal karyotypic young women diagnosed with POI have an increased risk of autoimmune hypothyroidism, and thus assessments of thyroid stimulating hormone, free thyroxine (T4), and antithyroid peroxidase and antithyroglobulin antibodies should be taken [31] .
In regard to clinical evaluation, timely identification of abnormal immunological activity in the setting of suspected POI could help to confirm a diagnosis of autoimmune POI and theoretically restore ovarian function with early administration of appropriate immunosuppressive treatment regimen. Previous research has also investigated inflammatory markers and their utility as a potential biomarker for POI. A recent study comparing neutrophil to lymphocyte ratio (NLR) between POI cases and normal controls found that NLR was significantly lower in POI cases (P < 0.001) and that an NLR ratio 1.5 or less was an independent risk factor for POI [32] . Although increases in NLR are associated with increases in the severity of inflammatory disorder, prior literature has proposed that lower NLRs are associated with the presence of autoimmunity or chronic inflammation. Further investigations examining the diagnostic accuracy of NLR are warranted. NLR could potentially serve to identify immunological abnormalities, thereby narrowing the field of potential causes for a particular case of POI. A more accurate determination of the cause of POI will help to establish more specialized treatment regimens thereby potentially producing more effective outcomes.
Bone turnover markers
Age and menopausal status-related changes in bone turnover markers have been observed in POI, and they may thus serve as an assessment for routine BMD monitoring in POI management. Commonly measured bone turnover markers include bonespecific alkaline phosphatase (bALP) and procollagen type I C-peptide, both bone formation markers, and cross-linked N-telopeptides of type I collagen (NTX), a marker of bone resorption. In a recent study examining the impact of POI on bone turnover markers, all bone turnover markers, bALP, NTX, and procollagen type I C-peptide, were significantly negatively correlated in women with POI [33 & ]. When stratified into two age subgroups using the age of 30 -the age at approximate peak BMD -as a cutoff, POI patients younger than 30 years of age had significantly lower lumbar t-scores compared with POI patients aged 30 years or older (mean AE standard deviation: À1.84 AE 1.47 vs. À1.06 AE 0.93; P < 0.021). The authors also reported that POI patients under 30 years of age had higher bALP [mean (U/l) AE SD: 48.99 AE 42.16 vs. 23.76 AE 10.08; P ¼ 0.004] and NTX levels [mean (nmol) AE SD: 58.80 AE 21.32 vs. 41.10 AE 11.37; P < 0.001]. Estrogen deficiency may thus have a greater impact on BMD decline in younger women with POI, particularly if they have not yet reached peak BMD, as previous research shows that increases in bone turnover markers are associated with an increased risk of adverse bone health including bone fracture [34] . However, reference intervals for bone turnover markers have not been fully established because of variations between studies from potentially nonequivalent study populations based on differing inclusion and exclusion factors [35] [36] [37] [38] [39] . Further efforts to establish standardized assessment methods and reference values are needed to effectively utilize bone turnover markers in POI management.
Alternative management strategies
In conjunction with HRT, mainstay lifestyle management approaches and regimens to maintain BMD include weight-bearing exercises, promotion of increased calcium and vitamin D through diet and/or supplementation, and cessation of alcohol and tobacco [40 & ]. For women with POI who are not taking HRT because of contraindications or personal decision, it is well known that these alternative management strategies are insufficient in preventing the decline in BMD [40 & ]. Additionally, none of these lifestyle recommendations can help treat menopausal symptoms. As such, women under this protocol should receive routine BMD every 6-12 months [40 & ]. Currently, there is limited evidence to support the efficacy of nonhormonal treatment options such as complementary therapies, selective serotonin reuptake inhibitors (SSRIs), venlafaxine or gabapentin. In a study of 31 POI patients investigating the therapeutic efficacy of acupuncture, 3 months of acupuncture administered three times a week resulted in significant reductions in average serum follicle stimulating hormone (P < 0.01) and luteinizing hormone (P < 0.01), as well as a significant increase in average serum estradiol (P < 0.01) [41] . Significant reductions in Self-Rated Anxiety Score following treatment were also reported (P < 0.001). However, as the study group comprised only 31 patients, such results may not fully represent the response of women with POI to acupuncture. Based on current research, these alternative regimens may be helpful in alleviating menopausal symptoms, but their ability to reduce the long-term effects of estrogen deficiency is controversial and thus they are not recommended for routine management.
Psychopharmacological management
Treatment of depression is complicated in POI as SSRIs have historically been shown to be associated with a decrease in lower lumbar spine and hip BMDs after 5 years of use [42, 43] . Additionally, SSRIs and tricyclic antidepressants are associated with dosedependent increases in bone fracture risk [44] . However, such effects on bone metabolism have not been observed in the setting of estrogen deficiency, indicating that skeletal effects of antidepressants may be influenced by sex steroid levels [45 && ]. Additionally, in a very recent study investigating the effects of bupropion, an atypical antidepressant, on bone metabolism in ovariectomized rats, the treatment was osteoprotective, and dose dependently inhibited increases in bone turnover markers as well as inflammatory cytokines [45 && ]. Treatment also resulted in a complete remission of bone loss after 6 weeks of treatment at both low (30 mg/kg/day) and high doses (60 mg/kg/day). Although bupropion does not directly treat estrogen deficiency, it shows promise for POI patients diagnosed with depression in preventing osteoporotic sequelae.
CONCLUSION
Despite increase in emerging research, POI remains poorly understood because of its variable causes and complex morbidity. Establishing a diagnosis and its potential cause as quickly as possible is critical to prevent the precipitous increase in risk for chronic sequelae because of estrogen deficiency, including infertility, cardiovascular disease, osteoporosis, and neurocognitive decline. Additionally, effective management necessitates a multidisciplinary approach that incorporates HRT, fertility management, maintenance of BMD, diet and exercise, as well as routine screening, applicable psychopharmacological treatment, and psychosocial support. Continued research must be prioritized for the muchneeded establishment of evidence-based diagnosis and treatment guidelines. 12.
